Abstract:<h3>Introduction</h3> The global burden of non-alcoholic fatty liver disease (NAFLD) is growing, but its subsequent health consequences have not been thoroughly examined. We performed phenome-wide Mendelian randomization and disease-trajectory analyses to comprehensively assess the health outcomes of NAFLD. <h3>Methods</h3> PheWAS analyses were conducted to map the associations of NAFLD with a broad range of phenotypes among 415,707 European in UK Biobank. Disease-trajectory and comorbidity analyses were applied to visualize the sequential patterns of multiple comorbidities related to the occurrence of NAFLD. The associations jointly verified by PheWAS using observational and genetically predicted NAFLD were further replicated by two-sample MR analysis using data from the FinnGen study and international consortia. <h3>Results</h3> PheWAS analyses on 1,172 disease outcomes revealed the associations of NAFLD with intrahepatic (e.g., chronic liver diseases and neoplasms) and extrahepatic diseases, including circulatory diseases (i.e., various cardiac diseases, hypertension and cerebrovascular diseases), metabolic diseases (i.e., hyperlipidemia and diabetes mellitus), genitourinary system diseases (i.e., renal failure), neurological disorders (i.e., dementias and Alzheimer’s disease), gastrointestinal diseases (i.e., gastritis, duodenitis and ulcerative colitis) and hematologic diseases (i.e., thrombocytopenia). Disease-trajectory and comorbidity network analyses identified 3 major extrahepatic comorbidities clusters related to NAFLD, mainly in cardiovascular, metabolic, and inflammatory diseases. Two-sample MR analyses supported the causal associations between NAFLD and the risk of several intrahepatic disorders, cardio-metabolic diseases and ascites, but found no associations with neurological diseases (i.e., dementia). <h3>Conclusions</h3> A prior diagnosis of NAFLD was associated with an increased risk of various extrahepatic diseases of circulatory, metabolic, genitourinary, gastrointestinal and possibly neurological systems. Three major sequential patterns of comorbidities related to NAFLD were identified, contributing to development of combination interventions targeting distinct pathways for the health promotion among NAFLD patients.

The Inter-Organ Crosstalk Reveals an Inevitable Link between MAFLD and Extrahepatic Diseases

New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut-Liver-Heart Crosstalk

MAFLD as part of systemic metabolic dysregulation

Associations between metabolic dysfunction-associated fatty liver disease and atherosclerotic cardiovascular disease

MAFLD: Renovation of clinical practice and disease awareness of fatty liver

Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease

A Simpler Definition of MAFLD Precisely Predicts Incident Metabolic Diseases: a 7-Year Cohort Study

Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD)

Underlying Mechanisms behind the Brain-Gut-Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An Update

Metabolic Associated Fatty Liver Disease as a Risk Factor for the Development of Central Nervous System Disorders

Associations Between Metabolic Dysfunction-Associated Fatty Liver Disease and Extrahepatic Cancers: a Cohort in China

Multisystem health consequences of nonalcoholic fatty liver disease: phenome-wide Mendelian randomization and disease-trajectory analyses

Metabolic Associated Fatty Liver Disease Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12 620 736 Individuals

An international multidisciplinary consensus statement on MAFLD and the risk of CVD

MAFLD: a multisystem disease

The Health Impact of MAFLD, a Novel Disease Cluster of NAFLD, is Amplified by the Integrated Effect of Fatty Liver Disease-Related Genetic Variants

Metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease from clinical to pathological characteristics: a multi-center cross-sectional study in real world

Metabolic-associated fatty liver disease and the risk of cardiovascular disease

Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention

Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China

Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight